The Company

Augurex Life Sciences Corp. develops biomarker technologies to screen people for diseases that when identified can be promptly treated, thereby delivering the benefit of earlier detection and greater treatment success. Biomarker screening tools can also be used to optimize a person’s therapy by predicting which treatment will personally offer them maximum therapeutic benefit while minimizing their side effects. Hence our signature; Identify, Optimize, Personalize.

Augurex’s lead technology, AGX-020 is a novel biomarker of arthritis which is being developed as a simple blood test to help doctors determine the degree of structural damage in the joint, thereby providing an alternative to x-rays.

Augurex identifies early-stage biomarkers and focuses on their scientific and clinical advancement while partnering their commercial entry into the market, thereby making them globally accessible to patients and healthcare providers.